about
Restrictive versus liberal red blood cell transfusion strategies for patients with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem cell supportSystematic review of randomized controlled trials of hematopoietic stem cell mobilization strategies for autologous transplantation for hematologic malignanciesClinical outcomes of immunoglobulin use in solid organ transplant recipients: protocol for a systematic review and meta-analysisOutcomes of both abbreviated hyper-CVAD induction followed by autologous hematopoietic cell transplantation and conventional chemotherapy for mantle cell lymphoma: a 10-year single-centre experience with literature reviewOptimal transfusion practices after allogeneic hematopoietic cell transplantation: a systematic scoping review of evidence from randomized controlled trials.Acquired Factor XIII Inhibitor in Hospitalized and Perioperative Patients: A Systematic Review of Case Reports and Case Series.Older patients with myeloma derive similar benefit from autologous transplantation.Impact of platelet transfusion on toxicity and mortality after hematopoietic progenitor cell transplantation.Rationale and design of platelet transfusions in haematopoietic stem cell transplantation: the PATH pilot studyThe influence of social support on hematopoietic stem cell transplantation survival: a systematic review of literatureThe impact of prolonged storage of red blood cells on cancer survival.Transplantation of umbilical cord blood-derived cells for novel indications in regenerative therapy or immune modulation: a scoping review of clinical studies.Transfusion of red cells in hematopoietic stem cell transplantation (TRIST): study protocol for a randomized controlled trial.Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation.Protocol for updating a systematic review of randomised controlled trials on the prophylactic use of intravenous immunoglobulin for patients undergoing haematopoietic stem cell transplantationThe use of intravenous antibiotics at the onset of neutropenia in patients receiving outpatient-based hematopoietic stem cell transplantsSystematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation.Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cellsRates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis.Effectiveness and safety of thiotepa as conditioning treatment prior to stem cell transplant in patients with central nervous system lymphoma.A plerixafor-based strategy allows adequate hematopoietic stem cell collection in poor mobilizers: results from the Canadian Special Access Program.Impact of ethnicity on human umbilical cord blood banking: a systematic review.Noninfectious pulmonary complications after hematopoietic stem cell transplantation: practical approach to imaging diagnosis.A systematic review of preclinical studies on the therapeutic potential of mesenchymal stromal cell-derived microvesicles.Current trends in clinical studies of allogeneic hematopoietic stem cell transplantation.A national survey of screening and management of hypogammaglobulinemia in Canadian transplantation centers.A single-institution analysis of the utility of pre-induction ejection fraction measurement in patients newly diagnosed with acute myeloid leukemia.Revised International Staging System Applied to Real World Multiple Myeloma Patients.Myasthenia Gravis Treated With Autologous Hematopoietic Stem Cell Transplantation.Improved Prediction of CD34+ Cell Yield before Peripheral Blood Hematopoietic Progenitor Cell Collection Using a Modified Target Value-Tailored Approach.Bortezomib-containing regimens (BCR) for the treatment of non-transplant eligible multiple myeloma.Is cytomegalovirus testing of blood products still needed for hematopoietic stem cell transplant recipients in the era of universal leukoreduction?Importance of factors influencing the decision to proceed with cord blood transplantation in adults: results of a Web-based survey of the Canadian transplant community.Rh D alloimmunization in allogeneic HSCT.Storage time of transfused red blood cells and impact on clinical outcomes in hematopoietic stem cell transplantation.Thromboprophylaxis for catheter-related thrombosis in patients with cancer: a systematic review of the randomized, controlled trials.Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time.Network geometry of evidence from randomised controlled trials addressing donor selection and source of haematopoietic progenitor cells used in allogeneic transplantation: a systematic scoping review.Balancing give and take between patients and their spousal caregivers in hematopoietic stem cell transplantation.Long-term graft function following autologous hematopoietic cell transplantation and the impact of preemptive plerixafor in predicted poor mobilizers.
P50
Q24193943-EE73CEC9-98E9-4445-B1B7-60644BFEEBADQ27011514-79B5F598-C024-4C07-97D1-4F08EF5CBBACQ27024904-151737F6-16F9-4266-885C-073D043ECAD4Q28087748-B024A536-B7F0-42C8-8B63-C9C93E06150BQ30248755-0BC85FF7-F192-4D21-AA30-FF7A9433C6E7Q30250345-DE415B89-969E-453D-898D-32A9E24AE525Q30370038-E9327FF0-A0E7-4090-9478-758A5336E545Q33417080-A6FB5B8F-285F-4655-88D6-3EDC9465008CQ33436425-AA9CAA23-7D46-48AA-B79A-22F31C6A1806Q34700451-774E0BBE-305F-466C-8B41-75AA62E2871EQ34851314-5DD39F7F-DEA9-45C7-9ACE-7442A7653387Q34997855-60B4B74C-CAC9-4B0E-B300-5A06271D21D5Q35277065-888FBF0D-3D95-42FA-B650-FEA170B73734Q35994520-5B4A4851-C802-43E6-BDAB-04C2CD4EF40EQ35999034-AF4C6AED-08BF-42DC-A6DD-5D23B60F463BQ36287292-3F1A9F97-786A-4449-98FE-F2196FCFB730Q36714830-A548BAB5-6212-4950-8F19-6FDA5CFBCCF5Q37015691-09398A3A-2BF2-446D-9DDD-62DCA81D0AC4Q37831402-A7978B7A-448A-4764-87FA-A72BCC931090Q38184642-F064052F-B974-46F4-9428-FDC4D16BCABAQ38194916-A2B32A4E-1AEA-418D-839D-D569182E7D26Q38201798-309BB0C0-0BAB-4011-A899-7D5E839EC451Q38211220-F8D7C3B7-3C51-48C3-8724-CB52D03F802EQ38236850-C70C79BA-B618-4571-90C0-EF5E3F6A831BQ38274881-5E4D59B0-91C9-46BD-B995-49BB4092A95CQ38830258-E113F4DF-D8EB-4AA0-977B-095C03C01355Q39198718-E7A401FB-0F36-442D-A14F-6B6D5A77AD9FQ39593828-B01D0B6D-8CCA-4A4C-9790-64692E69BECEQ39865114-08311762-0CAE-431A-9ED4-0F1DF8B590E6Q40236916-464B01D6-BBDD-4BED-AAAA-6E2AD604F8C5Q40386543-70059F9F-FA2D-48F6-95A0-B265F9C4B781Q42264356-1892545C-21FD-4B45-8D6E-F8B6B0AB545FQ45343049-C1931DCC-E4F1-43A3-8967-5291E5355831Q46021191-C45F8A35-3485-4174-906A-E6127F0B4C54Q46574814-C4659F5F-539B-4D24-9B87-574F37F8CD6AQ46885239-DBF0F6D5-8404-44F1-AB41-48C62D554975Q47562378-298FA12E-1256-4643-A16C-D5166076A9D3Q47704956-FBC6A95A-21F1-4973-971C-AFE5F5F7B320Q48905859-13F8D0A8-13BB-499E-A696-414B4E13F4E9Q49433149-170C1702-93F2-4585-8A3E-49B04E577AD6
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jason Tay
@ast
Jason Tay
@en
Jason Tay
@es
Jason Tay
@nl
type
label
Jason Tay
@ast
Jason Tay
@en
Jason Tay
@es
Jason Tay
@nl
prefLabel
Jason Tay
@ast
Jason Tay
@en
Jason Tay
@es
Jason Tay
@nl
P108
P106
P1153
23010386100
P31
P496
0000-0002-5969-9755